# The professional's toolkit: quick calculations and sanity checks
A pharma CEO tells investors her new drug will hit "$2 billion in peak sales." A competitor's slide deck claims "18% market sharemarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition →." A generics maker warns of "70% price erosion within a year of patent expiry." How would you know if any of these numbers are plausible without a finance degree or a Bloomberg terminal?
You run the numbers yourself, fast, on the back of an envelope. This lesson walks through a sample product P&L (profit and loss statement) and teaches you the five calculations that let you sanity-check almost any pharma claim in under two minutes.
Gross-to-net (GTN) is the gap between a drug's list price (what's published) and its net price (what the manufacturer actually collects after rebates, discounts, and fees).
In the US, this gap is large because of rebates paid to PBMs (pharmacy benefit managers, the middlemen who negotiate formulary placement for insurers) and discounts required under
Worked example:
GTN discount = (1,000 − 550) / 1,000 = 45%
As of 2024-2025 estimates, industry-wide average GTN discounts in the US run 40-50% for branded drugs overall, and can exceed 70-80% for crowded categories like insulins or diabetes drugs (source: drugchannels.net, a widely cited independent industry blog). Always ask "list or net?" before reacting to a price headline.
Market shareMarket shareThe percentage of total industry sales your company captures in a given period. It measures competitive position relative to rivals in a defined market.View full definition → claims usually come from prescription-tracking data sold by firms like IQVIA (the dominant global health data and analytics provider). Two share metrics matter, and they tell different stories:
Worked example:
A drug has 40,000 TRx out of a category total of 500,000 TRx.
TRx share = 40,000 / 500,000 = 8%
If that same drug has 12,000 NRx out of 100,000 category NRx:
NRx share = 12%
NRx share above TRx share means the drug is *gaining* ground (it's grabbing new patients faster than its installed base implies). NRx below TRx signals decline. This is the single fastest way to check whether a "market leader" claim is backward-looking or genuinely accelerating.
Peak sales is the maximum annual revenue a drug is expected to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → before generic or competitive erosion. The basic formula:
Peak sales = Eligible patient population × Diagnosis rate × Treatment rate × Drug's market share × Net price × Persistence rate
Worked example (illustrative, not a real drug):
Peak sales = 120,000 × $15,000 × 0.80 = $1.44 billion
Compare that to the "$2 billion" claim from our opening. If a company's assumptions require, say, a 35% share or near-100% persistence to hit that number, you now know exactly which assumption to interrogate on the earnings call.
When a drug loses patent protection (or in Europe, when the SPC, supplementary protection certificate extending patent life, expires), generic competitors enter and prices collapse. This is governed in the US partly by the Hatch-Waxman Act, which grants the first generic filer 180 days of exclusivity.
Typical erosion patterns (US, small-molecule drugs, estimates):
Europe tends to show slower volume erosion but steeper price cuts, driven by reference pricing systems where national payers cap prices based on the cheapest available generic.
Quick sanity check formula:
Remaining brand revenue (Year 2 post-LOE) ≈ Pre-LOE revenue × (1 − volume loss%) × (1 − price cut%)
Example: $1 billion pre-LOE (loss of exclusivity) revenue, 80% volume loss, 70% price cut:
$1B × 0.20 × 0.30 = $60 million remaining. That's a 94% total revenue collapse, consistent with what's typically observed for small-molecule brands facing multiple generic entrants.
Biologics behave differently: biosimilars (near-copies of biologic drugs, which cannot be exactly replicated like small-molecule generics) typically erode brand share more slowly, often 20-40% share loss in year one, because physicians and payers are more cautious about switching.
Knowledge check
1. Why does gross-to-net (GTN) discounting matter when evaluating a pharma company's pricing claims?
2. A generics maker says a drug will see '70% price erosion' after patent expiry. What's the best first sanity check to apply, based on the toolkit approach in this lesson?
3. Why might industry-wide average GTN discounts be much higher (70-80%) in categories like insulins compared to the overall branded drug average (40-50%)?
4. Select ALL correct answers about why prescription-tracking data (e.g., from IQVIA) requires care when interpreting 'market share' claims.
Select all the correct answers.
5. Select ALL correct answers about the purpose of 'quick calculations and sanity checks' like GTN analysis for a pharma professional.
Select all the correct answers.
Before trusting any pharma forecast, check it against sector-wide benchmarks (2024-2025 estimates, large-cap pharma):
If a company's P&L shows R&D at 5% of revenue while claiming a robust late-stage pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition →, that's a red flag worth investigating. If a "generics" company reports 70% gross margins, check whether it actually has a branded or biosimilar portfolio driving that number.
For market-level context: the global pharmaceutical market was estimated at roughly $1.6-1.7 trillion in 2024 (source: IQVIA Institute reports), with the US representing close to 45-50% of global spending despite having about 4% of world population, a structural fact behind nearly every pricing and access debate in the sector.
🎬 [VIDEO: "How Drug Pricing Actually Works in the US" - youtube.com - search for recent explainers from Kaiser Family Foundation (KFF) or Marketplace on YouTube covering PBMs, rebates, and list vs. net pricing]
When you see a pharma number in the wild, run it through this filter:
1. List or net? (applies to any price or revenue figure)
2. TRx or NRx? (applies to any share claim)
3. What assumptions drive the peak sales number? (population, share, price, persistence)
4. Small molecule or biologic? (determines expected erosion speed and pattern)
5. US or ex-US? (drivers, payers, and pricing mechanics differ sharply)